SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Lumexa Imaging Holdings, Inc. Common Stock LMRI NASDAQ

NASDAQ Global Select • Healthcare • Medical - Devices • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) is a Medical - Devices company in the Healthcare sector, currently trading at $9.99. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 2 out of 7 criteria passed.

Financials: revenue is $1.0B, +4.6%/yr average growth. Net income is $47M (loss), growing at +36.5%/yr. Net profit margin is -4.6% (negative). Gross margin is 11.5% (+0.9 pp trend).

Balance sheet: total debt is $961M against $586M equity (Debt-to-Equity (D/E) ratio 1.64, leveraged). Current ratio is 1.27 (adequate). Debt-to-assets is 54.5%. Total assets: $1.8B.

Analyst outlook: 1 / 1 analysts rate LMRI as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 73/100 (Pass), Past 0/100 (Fail), Health 17/100 (Fail), Moat 36/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

LMRI SharesGrow Score Overview

47/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 73/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 17/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 36/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LMRI

No analyst coverage available for this stock.

LMRI: +4.6%/yr revenue is, +36.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet LMRI: Debt-to-Equity (D/E) ratio 1.64 (leveraged), Current ratio is 1.27 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

LMRI: Gross margin is 11.5% (+0.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 36/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate LMRI as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

LMRI: Net profit margin is -4.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range7.23-19.45

Volume618.99K

Avg Volume (30D)826.74K

Market Cap$960.14M

Beta (1Y)0.00

Share Statistics

EPS (TTM)-0.66

Shares Outstanding$70.98M

IPO Date2025-12-11

CEOCaitlin Zulla

Financial Highlights & Ratios

Revenue (TTM)$1.02B

Gross Profit$117.19M

EBITDA$82.12M

Net Income$-47.1M

Operating Income$26.73M

Total Cash$58.83M

Total Debt$960.91M

Net Debt$902.08M

Total Assets$1.76B

Price / Earnings (P/E)-15.1

Price / Sales (P/S)0.94

Analyst Forecast

Rating ConsensusStrong Buy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS5502491062

Price Chart

LMRI

Lumexa Imaging Holdings, Inc. Common Stock ↗ · NASDAQ Global Select

Healthcare • Medical - Devices

7.23 52WK RANGE 19.45

People Also View

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message